Chongqing Taiji Medical Research Institute

Chongqing Taiji Medical Research Institute is the primary research and development arm of the Taiji Group, one of China's largest pharmaceutical conglomerates. The institute focuses on the modernization of Traditional Chinese Medicine (TCM), the development of innovative chemical drugs (Class 1 and Class 2), and high-end generic formulations. It manages several national-level innovation platforms, including a National Enterprise Technology Center and a Post-doctoral Research Station. Following the strategic acquisition of its parent company by Sinopharm, the institute has integrated into the broader China National Pharmaceutical Group ecosystem. Its R&D portfolio is diverse, covering therapeutic areas such as digestive health, respiratory medicine, and cardiovascular disease.